Solid Biosciences and Stoke Therapeutics Get Fresh Bullish Analyst Backing with Big Upside Targets

Truist restarts Solid Biosciences at Buy/$20. JPMorgan backs Stoke Therapeutics at Overweight/$40. Cash into 2028.